Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) from ProteoGenix; catalogue ARO-A22697; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The powerful tool for biotech research.
As a vital component of the immune system, B2M/Beta-2-microglobulin plays a crucial role in the recognition and elimination of foreign invaders. However, when this protein is overexpressed, it can lead to various autoimmune diseases and cancer. That’s where Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) comes in – a highly specific and potent inhibitor of B2M that can be used for a wide range of applications in biotech research.
Our Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) is a single-domain antibody derived from camelid heavy-chain antibodies. This unique structure allows for a high binding affinity and specificity towards B2M, making it a valuable tool for studying the role of B2M in various diseases and developing potential treatments.
One of the main applications of Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) is in autoimmune disease research. By inhibiting B2M, this VHH can help researchers understand the underlying mechanisms of autoimmune diseases and potentially identify new therapeutic targets.
In addition, Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) can also be used in cancer research. As B2M is often overexpressed in cancer cells, inhibiting its activity with this VHH can provide valuable insights into the role of B2M in cancer progression and may lead to the development of new anti-cancer therapies.
Our Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) has been extensively tested and validated for its effectiveness in inhibiting B2M activity in various experimental models. From cell culture studies to in vivo animal models, this VHH has consistently shown its ability to specifically target and inhibit B2M, making it a reliable tool for biotech research.
In conclusion, Anti-Human B2M/Beta-2-microglobulin VHH (SAA2322) is a powerful and versatile tool for studying the role of B2M in autoimmune diseases and cancer. With its high specificity and potency, this VHH is an essential component in any biotech research arsenal. Order now and take your research to the next level.
ProteoGenix catalogue number ARO-A22697. For research use only.
Target: Beta-2-microglobulin, Beta-2-microglobulin form pI 5.3, B2M; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
